Actively Recruiting
The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
Led by Sun Yat-sen University · Updated on 2024-12-03
116
Participants Needed
1
Research Sites
212 weeks
Total Duration
On this page
Sponsors
S
Sun Yat-sen University
Lead Sponsor
C
Chinese PLA General Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Studies have shown that combination therapy of TACE with Lenvatinib could achieve better survival outcomes than TACE alone for hepatocellular carcinoma (HCC) at BCLC B stage. However, whether patients could benefit from the ablation for intermediate recurrent HCC (RHCC) is still need high quality clinical evidence. This study is to evaluate the efficacy of ablation combined with TACE and Lenvatinib for the intermediate-stage RHCC.
CONDITIONS
Official Title
The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years
- Diagnosed with recurrent hepatocellular carcinoma (RHCC) by imaging
- Intermediate-stage RHCC defined as two to three lesions with at least one larger than 3 cm or more than three tumors
- Tumor count no more than six, with maximum tumor diameter of 5 cm or less
- No evidence of cancer spread outside the liver or major blood vessel invasion
- Liver function classified as Child-Pugh class A or B
- Received TACE as initial treatment after tumor recurrence with no tumor progression afterward
- Life expectancy longer than 3 months
You will not qualify if you...
- Younger than 18 years or older than 75 years
- Primary intermediate-stage hepatocellular carcinoma (not recurrent)
- More than six recurrent tumors or a single recurrent tumor
- Tumor larger than 5 cm
- Presence of cancer spread outside the liver
- Invasion of major blood vessels by tumor thrombus
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese PLA General hospital
Beijing, None Selected, China, 100853
Actively Recruiting
Research Team
Q
Qunfang Zhou
CONTACT
F
Feng Duan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here